Luciferase-transduced A20
Luciferase-transduced A20 - Related Videos
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
0 Views •
2023
Here, we describe a method for transducing human T cells with luciferase to facilitate in vivo tracking of bispecific antibody-induced T cell trafficking to tumors in studies to evaluate the anti-tumor efficacy and mechanism of T cell-engaging bispecific antibodies.
08:12
Pressure Transducer: Calibration Using a Pitot-static Tube
0 Views •
2023
Source: Shreyas Narsipur, Mechanical and Aerospace Engineering, North Carolina State University, Raleigh, NC Fluid pressure is an important flow characteristic that is required to determine the aerodynamics of a system. One of the oldest and still existing pressure measurement systems is the manometer due to its accuracy and simplicity of operation. The manometer is generally a U-shaped glass tube that is partially filled with liquid, as shown in Figure 1. The U-tube manometer requires no...
02:01
Assessing Pseudovirus Infection Using Luciferase Reporter Assay
0 Views •
2026
Source: Chang, X., et al. Preparation of Pseudo-Typed H5 Avian Influenza Viruses with Calcium Phosphate Transfection Method and Measurement of Antibody Neutralizing Activity. J. Vis. Exp. (2021).This video demonstrates a luciferase-based assay to quantify pseudovirus infection in epithelial cells. The pseudovirus encodes the luciferase gene, which is expressed in infected cells. After washing, and cells are incubated with lysis buffer at an ultra-low temperature, and then thawed to induce lysis.
12:58
Transfecting RAW264.7 Cells with a Luciferase Reporter Gene
0 Views •
Cited by 13 •
2015
Transfection into the macrophage cell line, RAW264.7, is difficult due to the cell’s natural response against foreign materials. We described here a gentle yet robust procedure for transfecting luciferase reporter genes into RAW264.7 cells.
02:31
Sample Preparation for Luciferase-Based Viral Quantification
0 Views •
2026
Source: Garcia, V., et al. High-throughput Titration of Luciferase-expressing Recombinant Viruses. J. Vis. Exp. (91), e51890, doi:10.3791/51890 (2014).This video demonstrates the preparation of cell culture samples to assess viral load using a luciferase-based assay. It outlines the process of infecting epithelial cells with a genetically modified virus, transferring viral supernatants and standards into assay wells, and promoting viral entry through centrifugation and incubation. The...
FAQs
Signal interpretation depends on the light-producing activity of luciferase after substrate administration and on where the engineered cells are located. Consequently, emitted bioluminescence serves as an estimate of cell presence, distribution, and changes in burden rather than a direct tissue measurement. Tracking the signal over time helps reveal whether malignant B-cell populations are expanding, declining, or relocating.
Because the same malignant-cell population can be followed during an experiment, changes in emitted light can be compared with the timing of immune responses or interventions. A falling signal may be consistent with reduced detectable lymphoma-cell presence, whereas altered localization may indicate redistribution. This makes the model useful for examining how immune-cell activity affects malignant B cells in living animals.
Its main advantage is longitudinal observation: investigators can monitor the same model repeatedly instead of relying only on separate tissue collections at successive time points. This reduces the need for repeated sampling and preserves a continuous view of tumor progression or treatment response. The resulting time course can show changes that a single endpoint measurement would not capture.
A basic workflow pairs the engineered A20 cell model with substrate administration, followed by detection of emitted bioluminescence. Measurements can then be compared across time or experimental conditions to estimate cell presence, distribution, and tumor-burden changes. The essential readout is therefore a sequence of signal observations rather than a one-time tissue assessment.
In immunotherapy studies, serial bioluminescence can indicate whether an intervention changes the detectable lymphoma-cell population over time. Comparing signals between treated and untreated experimental conditions supports assessment of treatment-associated changes in tumor burden and localization. The model therefore connects therapy exposure with dynamic observations of malignant B-cell behavior in vivo.
Within immunology and infection research, the model provides a way to examine how host defenses or experimental treatments alter the survival and localization of malignant B cells. Investigators can use changes in the bioluminescent readout to follow these effects in vivo, linking immune or infection-related conditions to lymphoma behavior without relying exclusively on repeated tissue collection.